Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...

Insurers also ask the Trump administration, which is engaged in a sweeping campaign to eradicate anything related to diversity, equity and inclusion from the federal government, to eliminate or scale ...

Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the ...

Novo Nordisk's 2024 earnings exceeded estimates, with strong performance in diabetes, obesity, and rare disease segments.

Novo Nordisk NVO is scheduled to report fourth-quarter 2024 results on Feb. 5, 2025, before the opening bell. The Zacks ...

Novo Nordisk's recent decline suggests it may be a Buy again, with strong growth prospects in diabetes and obesity treatments ...

However, the data showed that while obesity is a risk factor, so is a lack of fitness — even if you’re not clinically obese. The studies suggest that people of healthy, average weight with the lowest ...

The companies Immunovant, Verdiva Bio, and Akero Therapeutics bagged the biggest biotech funding rounds overall in January ...

The FDA says new labels will make it easier to spot harmful ingredients. A UVA nutritionist suggests taking a holistic ...

Spokeo explored the negative impacts of smartphone usage on sleep and what people can do to get more restful downtime.

Detailed price information for Novo Nordisk A/S ADR (NVO-N) from The Globe and Mail including charting and trades.